PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE by S. V. KHOKHLOVA, O. A. SHILKINA

Subjects: Get full text

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme by Mary-Ann Xavier, Fernando Rezende, Ricardo Titze-de-Almeida, Bart Cornelissen

Subjects: Get full text

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer by Soupos Nikolaos, Laschos Konstantinos, Bournakis Evangelos, Kostouros Euthymios, Aravantinos Gerasimos

Subjects: “…parp-inhibitors…”
Get full text

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials by Alecu I, Milenkova T, Turner SR

Subjects: Get full text

PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature by Jagoda Niewiadomska, Wiktor Grela, Daria Furtak, Dawid Tulej, Paulina Głogowska, Alicja Dziedzic, Natalia Gniaź, Dominika Marciniuk, Natalia Marko, Aleksandra Górska

Subjects: “…PARP inhibitors…”
Get full text

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS by Jeanne M. Schilder, Amanda Golembesky, Tirza Areli Calderón Boyle, Gui Lan Ye, Judi Kuplast

Subjects: Get full text

First-line treatment of advanced ovarian cancer: an expert update by Branka Petrić-Miše

Subjects: Get full text

Emerging treatment options for ovarian cancer: focus on rucaparib by Mariappan L, Jiang XY, Jackson J, Drew Y

Subjects: Get full text

A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer by О. N. Churuksaeva, L. А. Kolomiets, А. B. Villert

Subjects: Get full text

PARP Inhibitors: A New Horizon for Patients with Prostate Cancer by Belén Congregado, Inés Rivero, Ignacio Osmán, Carmen Sáez, Rafael Medina López

Subjects: Get full text

Case report of two long term ovarian cancer survivors with brain metastases following multimodal treatment including chemotherapy, radiotherapy and maintenance olaparib: An institu... by Yukari Tsuchino, Tatsuyuki Chiyoda, Mitsuyo Jisaka, Tomomi Sakamaki, Momo Hirata, Mio Takahashi, Takuma Yoshimura, Kensuke Sakai, Michiko Wada, Wataru Yamagami

Subjects: Get full text

Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis by Shunlian Fu, Pingjin Zou, Zengyi Fang, Xinxiang Zhou, Junyang Chen, Cuicui Gong, Li Quan, Bing Lin, Qiu Chen, Jinyi Lang, Meihua Chen

Subjects: “…PARP inhibitors…”
Get full text

The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas by Nazanin Majd, Timothy A. Yap, W. K. Alfred Yung, John de Groot

Subjects: Get full text

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition... by Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, James W. Hodge

Subjects: “…PARP inhibitors…”
Get full text

PARP inhibitor-related haemorrhages: What does the real-world study say? by Shiyan Wang, Mengran Guo, Xiang Zhang, Ping Fan, Zhaohui Jin

Subjects: “…PARP inhibitors…”
Get full text

Use of First-Line PARP Inhibitors in Ovarian Cancer by Ursula Hasler-Strub

Subjects: Get full text

Tertiary Prevention of Ovarian Cancer After PARP Inhibitor Therapy by ZANG Rongyu

Subjects: Get full text

Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan by Chia-Chen Hsu, Yu-Bin Pan, Chyong-Huey Lai, Ting-Chang Chang, Lan-Yan Yang, Hung-Hsueh Chou

Subjects: Get full text

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer by Alessandra Anna Prete, Letizia Procaccio, Francesca Bergamo, Cosimo Rasola, Floriana Nappo, Vittorina Zagonel, Sara Lonardi

Subjects: Get full text

PARP Inhibitors in the Treatment of Ovarian Cancer by Andrzej Paweł Zuzak, Magdalena Cieślik-Porębska, Krzysztof Kułak, Jagoda Niewiadomska

Subjects: “…PARP inhibitors…”
Get full text